L‐ornithine L‐aspartate vs lactulose
Non‐serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 0.05 [0.01, 0.18]2 studies · 292 participantsVery low